Income Statement

v3.20.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS    
Revenues, net $ 240,259 $ 376,656
Operating expenses:    
Cost of implants and other costs 81,670 170,953
Research and development 1,125,098 151,768
Selling, general and administrative 4,565,346 4,422,600
Impairment of acquired license 250,000
Depreciation and amortization 29,413 7,353
Total operating expenses 5,801,527 5,002,674
Loss from operations (5,561,268) (4,626,018)
Other income (expenses):    
Interest expense, net (1,622,426) (1,959,207)
Gain on settlement of debt 847
Grant income 1,091,061
Loss on sale of fixed assets (1,902)
Other miscellaneous income 46,214
Total other income (expenses) (487,053) (1,958,360)
Net loss before provision for income taxes (6,048,321) (6,584,378)
Income taxes
Net Loss (6,048,321) (6,584,378)
Non-controlling interest 8,691 72,487
Net loss attributable to BioCorRx Inc. $ (6,039,630) $ (6,511,891)
Net loss per common share, basic and diluted $ (1.71) $ (2.60)
Weighted average number of common shares outstanding, basic and diluted 3,523,208 2,506,229

Source